High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: A positron emission tomography study using [11C]SA4503

International Journal of Neuropsychopharmacology

Volumn 12, Issue 8, 2009, Pages 1127-1131

  Ishikawa, Masatomo ^a,b,c   Sakata, Muneyuki ^b   Ishii, Kenji ^b   Kimura, Yuichi ^d   Oda, Keiichi ^b   Toyohara, Jun ^a,b   Wu, Jin ^a,b   Ishiwata, Kiichi ^b   Iyo, Masaomi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

1 receptor; 11C SA4503; Acetylcholinesterase inhibitor; Donepezil; PET

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; CARBON 11; DONEPEZIL; MU OPIATE RECEPTOR; CHOLINESTERASE INHIBITOR; CUTAMESINE; INDAN DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR;

ADULT; ARTICLE; CINGULATE GYRUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OCCIPITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SINGLE DRUG DOSE; TEMPORAL LOBE; TIME TO MAXIMUM PLASMA CONCENTRATION; BRAIN; BRAIN MAPPING; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RADIOASSAY; SCINTISCANNING;

ADMINISTRATION, ORAL; ADULT; BRAIN; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERAZINES; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTORS, SIGMA; YOUNG ADULT;

EID: 69749122515     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145709990204     Document Type: Article

References (23)

1. Blennow K, de Leon MJ, Zetterberg H (2006). Alzheimer's disease. Lancet 368, 387-403.
2. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, et al. (2005). Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry 76, 315-319.
3. Hashimoto K, Ishiwata K (2006). Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Current Pharmaceutical Design 12, 3857-3876.
4. Hayashi T, Su TP (2004). Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18, 269-284.
5. 2+ signaling and cell survival. Cell 131, 596-610.
6. Innis RB, Cunningham VJ, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27, 1533-1539.
7. 11C]SA4503. Biological Psychiatry 62, 878-883.
8. Ishima T, Fujita Y, Kohno M, Kunitachi S, et al. (2009). Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline. Open Clinical Chemistry Journal 2, 7-11.
9. Ishima T, Nishimura T, Iyo M, Hashimoto K (2008). Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 1656-1659.
10. 2-like receptors. Annals of Nuclear Medicine 20, 569-573.
11. Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, et al. (2002). Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Journal of Clinical Psychopharmacology 22, 615-620.
12. Kato K, Hayako H, Ishihara Y, Marui S, et al. (1999). TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons. Neuroscience Letters 260, 5-8.
13. 1 receptors. Nuclear Medicine and Biology 27, 255-261.
14. 1 receptor imaging. Annals of Nuclear Medicine 21, 533-535.
15. Kunitachi S, Fujita Y, Ishima T, Kohno M, et al. (2009). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Research 1279, 189-196.
16. Logan J, Fowler JS, Volkow ND, Wang GJ, et al. (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of Cerebral Blood Flow and Metabolism 16, 834-840.
17. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, et al. (1996). Binding properties of SA4503 a novel and selective sigma1 receptor agonist. European Journal of Pharmacology 306, 271-279.
18. 1 protein, but not N-methyl-D-aspartate receptor, is involved in the pharmacological activity of donepezil. Journal of Pharmacology and Experimental Therapeutics 317, 606-614.
19. 1 receptor. British Journal of Pharmacology 149, 998-1012.
20. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, et al. (1984). A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Annals of Neurology 15, 217-227.
21. Ohnishi A, Mihara M, Kamakura H, Tomono Y, et al. (1993). Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. Journal of Clinical Pharmacology 33, 1086-1091. (Pubitemid 24002899)
22. 11C]SA4503. Neuroimage 35, 1-8. (Pubitemid 46240943)
23. Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, et al. (2001). Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56, 408-410.